2014
Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments.
Neparidze N, Lacy J. Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments. Clinical Advances In Hematology And Oncology 2014, 12: 358-71. PMID: 25003566.Peer-Reviewed Original ResearchMeSH KeywordsEpstein-Barr Virus InfectionsHerpesvirus 4, HumanHumansLymphoproliferative DisordersNeoplasmsConceptsEpstein-Barr virusClinical featuresEBV-specific T-cell therapyInhibition of EBVTreatment of EBVT-cell lymphomaT-cell therapyNew treatment strategiesEBV vaccineImmune dysregulationHodgkin's lymphomaNasopharyngeal cancerTreatment strategiesGastric cancerTherapeutic approachesBurkitt's lymphomaEBV oncogenesisAntiviral drugsLymphoid neoplasmsViral infectionLymphomaImmunogenic propertiesLytic viral infectionPathobiologyMalignancy
2009
Harnessing CD1d‐Restricted T Cells toward Antitumor Immunity in Humans
Neparidze N, Dhodapkar MV. Harnessing CD1d‐Restricted T Cells toward Antitumor Immunity in Humans. Annals Of The New York Academy Of Sciences 2009, 1174: 61-67. PMID: 19769737, PMCID: PMC2782771, DOI: 10.1111/j.1749-6632.2009.04931.x.Peer-Reviewed Original ResearchConceptsNKT cellsT cellsAntitumor immunityType I NKT cellsType II NKT cellsNatural killer T cellsPresence of CD1dI NKT cellsKiller T cellsAdvanced myelomaNKT activationDendritic cellsImmune therapyAlpha-GalactosylceramideCancer patientsCD1d moleculesLipid antigensPreclinical studiesThalidomide analoguesCD1dDistinct subsetsAgonist ligandsPatientsCancerType I